TW200716541A - The preparation and use of compounds as protease inhibitors - Google Patents

The preparation and use of compounds as protease inhibitors

Info

Publication number
TW200716541A
TW200716541A TW095121030A TW95121030A TW200716541A TW 200716541 A TW200716541 A TW 200716541A TW 095121030 A TW095121030 A TW 095121030A TW 95121030 A TW95121030 A TW 95121030A TW 200716541 A TW200716541 A TW 200716541A
Authority
TW
Taiwan
Prior art keywords
compounds
formula
disclosed
methods
preparation
Prior art date
Application number
TW095121030A
Other languages
English (en)
Inventor
Brian A Mckittrick
Zhao-Ning Zhu
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37571011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200716541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200716541A publication Critical patent/TW200716541A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095121030A 2005-06-14 2006-06-13 The preparation and use of compounds as protease inhibitors TW200716541A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69054305P 2005-06-14 2005-06-14

Publications (1)

Publication Number Publication Date
TW200716541A true TW200716541A (en) 2007-05-01

Family

ID=37571011

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095121030A TW200716541A (en) 2005-06-14 2006-06-13 The preparation and use of compounds as protease inhibitors

Country Status (10)

Country Link
US (1) US20080113957A1 (zh)
EP (1) EP1896406A2 (zh)
JP (1) JP2008543846A (zh)
CN (1) CN101193859A (zh)
AR (1) AR054618A1 (zh)
CA (1) CA2610617A1 (zh)
MX (1) MX2007016186A (zh)
PE (1) PE20070073A1 (zh)
TW (1) TW200716541A (zh)
WO (1) WO2006138230A2 (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
RU2008100165A (ru) 2005-06-14 2009-07-20 Шеринг Корпорейшн (US) Ингибиторы аспартильных протеаз
CN101198609A (zh) * 2005-06-14 2008-06-11 先灵公司 天冬氨酰基蛋白酶抑制剂
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
AU2007332754A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
EP2200990A1 (en) 2007-09-06 2010-06-30 Schering Corporation Gamma secretase modulators
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
US8426595B2 (en) 2007-12-11 2013-04-23 Xianhai Huang Gamma secretase modulators
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
JP5503663B2 (ja) 2008-11-13 2014-05-28 メルク・シャープ・アンド・ドーム・コーポレーション ガンマセクレターゼモジュレータ
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
TW201034666A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
TW201035103A (en) 2008-12-22 2010-10-01 Schering Corp Gamma secretase modulators
EP2443121A2 (en) 2009-06-16 2012-04-25 Schering Corporation Gamma secretase modulators
US20120232108A1 (en) 2009-06-16 2012-09-13 Xianhai Huang Gamma secretase modulators
US20120245158A1 (en) 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2547685A1 (en) 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
MX2012010657A (es) 2010-03-15 2013-02-07 Amgen Inc Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
WO2012069428A1 (en) 2010-11-22 2012-05-31 Noscira, S.A. Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9221839B2 (en) 2011-04-07 2015-12-29 Merck Sharp & Dohme Corp. C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
WO2014062549A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2014062553A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
KR102220259B1 (ko) 2013-02-12 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Bace 매개 app 처리과정을 조절하는 히단토인
US20220267280A1 (en) * 2019-08-16 2022-08-25 Purdue Research Foundation Small molecule stimulators of the core particle of the proteasome
CN114702591B (zh) * 2022-05-17 2022-09-23 诺赛联合(北京)生物医学科技有限公司 成体细胞衍生的类器官制备技术

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1168896B (de) * 1962-06-16 1964-04-30 Hoechst Ag Verfahren zur Herstellung von N, N-disubstituierten Amidinen
DE2235177A1 (de) * 1972-07-18 1974-02-07 Bayer Ag Verfahren zur herstellung von lactamhydrazonen aromatischer systeme
WO2003074467A2 (en) * 2002-03-04 2003-09-12 Procyon Biopharma Inc. Urea derivatives as hiv aspartyl protease inhibitors
MY149978A (en) * 2003-12-15 2013-11-15 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
AU2005264917A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase

Also Published As

Publication number Publication date
CA2610617A1 (en) 2006-12-28
PE20070073A1 (es) 2007-03-08
AR054618A1 (es) 2007-07-04
EP1896406A2 (en) 2008-03-12
JP2008543846A (ja) 2008-12-04
WO2006138230A3 (en) 2007-04-12
WO2006138230A2 (en) 2006-12-28
CN101193859A (zh) 2008-06-04
MX2007016186A (es) 2008-03-07
US20080113957A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
TW200716541A (en) The preparation and use of compounds as protease inhibitors
TW200716574A (en) The preparation and use of compounds as aspartyl protease inhibitors
HRP20130664T1 (en) Heterocyclic aspartyl protease inhibitors
MY149183A (en) Heterocyclic aspartyl protease inhibitors
WO2006065277A3 (en) Heterocyclic aspartyl protease inhibitors
WO2006138265A3 (en) Heterocyclic aspartyl protease inhibitors, preparation and use thereof
MX2009006227A (es) Inhibidores de aspartil proteasa que contienen un sistema de anillo triciclico.
TW200716644A (en) Aspartyl protease inhibitors
SG162790A1 (en) Aspartyl protease inhibitors
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
WO2005037825A3 (en) Protein kinase inhibitors
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
WO2007050721A3 (en) Heterocyclic aspartyl protease inhibitors
TW200716645A (en) Macrocyclic heterocyclic aspartyl protease inhibitors
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
WO2007143523A8 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
EP1688420A4 (en) 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
MY133527A (en) Isoquinoline derivatives
WO2004060862A3 (en) Compounds having prolyl oligopeptidase inhibitory activity
TW200619203A (en) Heterocyclic aspartyl protease inhibitors